
    
      Secondary objectives include:

        -  to characterize progression-free survival

        -  to characterize time to progression

        -  to determine response duration

        -  to characterize the effect of study drug on health-related quality of life

        -  to explore the correlation of positron emission tomography (PET) scan results with
           objective responses observed with conventional imaging in this patient population

        -  to characterize the immunogenicity response of MDX-060

        -  to characterize the safety of MDX-060, and

        -  to characterize the pharmacokinetic profile of MDX-060
    
  